
EP Edge® × HRS: Rethinking the Defaults: AFib Ablation vs Antiarrhythmics, Flecainide Beyond CAST, and Physiologic Pacing
Episode 42
In this EP Edge and Heart Rhythm Society collaborative podcast, Dr. Niraj Sharma and Dr. Mike Lloyd examine new evidence challenging several long-standing assumptions in cardiac electrophysiology: when to choose catheter ablation over antiarrhythmic drug therapy for atrial fibrillation, whether left bundle branch area pacing should replace conventional right ventricular pacing in patients who require substantial ventricular pacing, and how broadly the lessons of CAST should continue to restrict flecainide and other Class Ic antiarrhythmic drugs. The atrial fibrillation discussion brings together two complementary 2026 Heart Rhythm meta-analyses. Demy L. Idema and colleagues evaluated antiarrhythmic drugs versus catheter ablation for rhythm control across randomized controlled trials, focusing on AF recurrence, hospitalization, mortality, and treatment-related complications. Marwan Shawki and colleagues examined the safety of catheter ablation versus antiarrhythmic drugs across 24 randomized trials involving 6,665 participants. Together, the studies raise an important contemporary question: as ablation becomes more effective and procedural safety improves, does antiarrhythmic drug therapy still deserve an automatic position ahead of ablation in the AF treatment pathway? The discussion then turns to physiologic pacing and the PACE-HF trial by Jenish P. Shroff and colleagues, published in the European Heart Journal.
Publisher
EP Edge Journal Watch: Cardiac Electrophysiology Research
Link
share.transistor.fm/s/022f07f4
Published
August 31, 2026
Duration
38 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Niraj Sharma MD FACC FHRS: Cardiac Electrophysiology & Cardiology
EP Edge Journal Watch: Cardiac Electrophysiology Research
@epedgejournalwatchcardiacele
#afibablation #antiarrhythmics #physiologicpacing #lifesciences #medicine
